Analyzing the Obesity Market Landscape

DelveInsight's Obesity Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, market share, and the forecasted market size from 2020 to 2034. The report covers the 7MM, including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Request for Sample report @ Obesity Market

Key Takeaways from the Obesity Market Report

DelveInsight's analysis reveals that the obesity market in the US was valued at USD 1.2 billion in 2022. The prevalent population of obesity in the United States in 2023 was 114 million cases, a number expected to rise by 2034. Leading companies like Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, and Rhythm Pharmaceuticals are developing novel obesity drugs expected to enter the market in the coming years. The pipeline includes therapies such as Oral semaglutide, Danuglipron (PF-06882961), Survodutide (BI 456906), and others. Significant developments include the FDA's approval of Eli Lilly's ZEPBOUND (tirzepatide) injection in November 2023 and Pfizer's promising Phase IIb clinical trial results for danuglipron (PF-06882961) in December 2023.

Obesity Overview

Obesity is a chronic condition characterized by excessive body fat and metabolic implications beyond physical size. It involves a complex interplay of genetic and environmental factors. Genetic predispositions, such as mutations in the leptin-melanocortin axis, contribute to severe and early-onset forms of obesity. Excess adipose tissue, high blood pressure, and a BMI exceeding 30 kg/m² are common indicators. Obesity often leads to social stigma, discrimination, low self-esteem, and depression. Childhood obesity can result in similar complications as adult obesity, sometimes even earlier.

Obesity Epidemiology Segmentation

DelveInsight's report provides an epidemiological analysis for the study period from 2020 to 2034. The US accounted for 61% of adult cases and 66% of children cases in 2023. The report segments the data into total prevalent cases, patients seeking help, and treated cases of obesity.

Obesity Treatment Market

Weight reduction through nutritious eating, physical activity, and lifestyle modifications are common treatments for obesity. Weight management programs can help, but some individuals may need weight-loss medications, devices, or bariatric surgery. Emerging techniques like hydrogels, vagal nerve blockade, and gastric aspirate highlight the ongoing progress in combating obesity.

FDA-approved treatments include CONTRAVE (bupropion-naltrexone), SAXENDA (liraglutide), Alli and XENICAL (orlistat), QSYMIA (phentermine-topiramate), IMCIVREE (setmelanotide), and WEGOVY (semaglutide). These therapies vary in mechanisms, from reducing appetite to blocking pancreatic lipase or influencing stomach emptying.

Obesity Pipeline Therapies and Key Companies

The obesity pipeline features promising drugs like Oral semaglutide (Novo Nordisk), Danuglipron (Pfizer), Survodutide (Boehringer Ingelheim), and others. RYBELSUS (oral semaglutide) is approved for type II diabetes and is under development for obesity treatment. Pfizer's danuglipron showed significant weight reduction in a Phase IIb trial.

Other late-stage therapies include Liraglutide, Cagrilintide, Orforglipron, Setmelanotide, Carbetocin, Pitolisant, and DCCR. These emerging therapies are expected to transform the market landscape, offering new standards of care and opportunities for medical innovation and economic growth.

Request for Sample report @ Obesity Market

Obesity Market Dynamics

The obesity market is set to evolve with increased investment in drug research and development. Emerging mobile technologies offer unprecedented possibilities for understanding and intervening in obesity. Key players like Novo Nordisk and Eli Lilly are addressing unmet needs, while governmental and nongovernmental bodies work to raise awareness, expanding the market as patients seek treatment.

The treatment space will significantly impact the obesity market during the forecast period, driven by the introduction of emerging therapies with improved efficacy and better diagnosis rates. However, several factors may impede market growth, including the lack of consensus on the best treatment, disparities in disease staging systems, and comorbidities requiring additional treatments.

The economic burden of obesity, high absenteeism, unemployment, psychosocial issues, and market access challenges also threaten market growth. Failures and discontinuation of emerging therapies, unaffordable pricing, and a shortage of healthcare specialists further complicate the landscape. Undiagnosed and unreported cases and lack of awareness about the disease may also impact growth.

Conclusion

DelveInsight's Obesity Market Insights report offers a comprehensive analysis of the obesity market landscape from 2020 to 2034. With emerging therapies poised to reshape the market, significant opportunities exist for medical innovation and economic growth. However, addressing challenges related to treatment efficacy, economic burden, and awareness is crucial for realizing the full potential of these advancements. The report's insights provide valuable guidance for stakeholders navigating the evolving obesity market landscape.

Trending Reports:

DelveInsight:

| Go Pro | AZ1 Chatter | IMYO FYI | Tell your friends and family about INSTATEL & AZ1 |